Jenburkt Pharmaceuticals Limited (BOM:524731)

Jenburkt Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	708.91	55.77	73.65	41.25	36.6	50.31
Short-Term Investments	106.2	417.39	157.79	698.44	458.25	415.55
Cash & Short-Term Investments	815.11	473.16	231.43	739.69	494.84	465.86
Cash Growth	744.82%	104.45%	-68.71%	49.48%	6.22%	-10.42%
Accounts Receivable	198.26	243.57	207.35	194.75	169.62	152.07
Other Receivables	7.88	53.95	11	50.02	42.28	21.31
Receivables	209.46	298.15	218.87	245.67	213.08	175.28
Inventory	150.97	138.1	88.8	85.66	83.38	98.98
Prepaid Expenses	-	11.89	11.59	6.77	4.59	5.53
Other Current Assets	33.95	29.59	14.61	19.49	15.02	13.39
Total Current Assets	1,209	950.89	565.32	1,097	810.91	759.04
Property, Plant & Equipment	765.32	653.4	547.06	112.14	112.19	113.05
Long-Term Investments	337.9	580.55	765.4	173.9	344.09	415.71
Other Intangible Assets	2.8	2.41	2.28	3.88	1.87	3.06
Long-Term Deferred Tax Assets	25.05	23.99	14.69	7.98	4.25	3.71
Other Long-Term Assets	8.59	48.82	66.93	255.51	144.23	133.59
Total Assets	2,349	2,260	1,962	1,651	1,418	1,429

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	78.11	81	81.55	62.57	60.97	71.1
Accrued Expenses	74.9	65.93	16.04	9.31	2.55	2.59
Short-Term Debt	-	-	19.79	-	24.39	58.15
Current Portion of Leases	7.06	6.49	4.23	-	4.89	4.51
Current Income Taxes Payable	-	11.38	2.86	16.41	3.37	0.77
Other Current Liabilities	77.62	66.68	63.72	75.49	61.46	75.67
Total Current Liabilities	237.69	231.47	188.19	163.79	157.62	212.8
Long-Term Leases	15.46	18.4	14.92	-	-	4.89
Long-Term Deferred Tax Liabilities	16.57	9.76	10.87	7.9	7.18	8.56
Other Long-Term Liabilities	30.1	30.1	30.1	29.91	29.43	29.43
Total Liabilities	299.82	289.72	244.09	201.59	194.22	255.67

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	44.13	44.13	44.13	44.13	44.13	45.89
Retained Earnings	-	1,935	1,657	1,375	1,165	1,119
Comprehensive Income & Other	2,005	-8.85	16.76	30.62	15.25	9.2
Shareholders' Equity	2,049	1,970	1,718	1,449	1,224	1,174
Total Liabilities & Equity	2,349	2,260	1,962	1,651	1,418	1,429

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	22.52	24.88	38.94	-	29.28	67.55
Net Cash (Debt)	792.59	448.28	192.5	739.69	465.57	398.31
Net Cash Growth	898.14%	132.88%	-73.98%	58.88%	16.89%	-15.15%
Net Cash Per Share	179.60	101.57	43.62	167.61	101.97	86.79
Filing Date Shares Outstanding	4.41	4.41	4.41	4.41	4.41	4.59
Total Common Shares Outstanding	4.41	4.41	4.41	4.41	4.41	4.59
Working Capital	971.81	719.43	377.12	933.49	653.29	546.24
Book Value Per Share	464.29	446.47	389.23	328.42	277.32	255.77
Tangible Book Value	2,047	1,968	1,715	1,446	1,222	1,171
Tangible Book Value Per Share	463.66	445.92	388.71	327.54	276.90	255.10
Buildings	-	125.58	117.96	107.24	103.86	101.39
Machinery	-	234.37	237.32	206.45	193.64	191.2
Construction In Progress	-	461.19	402.77	12.41	9.57	2.12

Data Source: S&P Global Market Intelligence Last updated: Nov 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error